Superluminal Medicines
Drug DiscoveryWebsite
Superluminal Medicines valuation and funding history | Last updated: August 26, 2025 | 3 funding rounds
Current Valuation
N/A
As of August 26, 2025
Total Funding Raised
$157.7M
Across 3 rounds
Last Round
Early Stage VC
$5.0M
Last Funding
Aug 2025
Funding date
Capital Efficiency
N/A
Valuation / Funding
Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones
| Date | Round | Amount | Post-Valuation | Growth |
|---|---|---|---|---|
| N/A | Unknown | Undisclosed | N/A | - |
| January 24, 2025 | Early Stage VC (Series A) | $120.0M | N/A | - |
| August 28, 2023 | Seed Round | $32.7M | N/A | - |
Valuation Analysis
Current Valuation Metrics
Superluminal Medicines is currently valued at N/A as of August 26, 2025. The company has raised a total of $157.7M in funding across 3 funding rounds.
Explore More Data
Detailed analysis for Superluminal Medicines
What is Superluminal Medicines Worth in 2026?
Superluminal Medicines is a leading private company in the Drug Discovery sector. Track Superluminal Medicines's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.
How Superluminal Medicines Valuation is Determined
Private company valuations like Superluminal Medicines's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.